SG11201909064RA - Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer - Google Patents

Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Info

Publication number
SG11201909064RA
SG11201909064RA SG11201909064RA SG11201909064RA SG 11201909064R A SG11201909064R A SG 11201909064RA SG 11201909064R A SG11201909064R A SG 11201909064RA SG 11201909064R A SG11201909064R A SG 11201909064RA
Authority
SG
Singapore
Prior art keywords
international
combination
pct
antibody
dna
Prior art date
Application number
Inventor
Astrid Zimmermann
Lars Damstrup
Anne-Kathrin Prokein
Andreas Schroeder
Original Assignee
Merck Patent Gmbh
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Pfizer filed Critical Merck Patent Gmbh
Publication of SG11201909064RA publication Critical patent/SG11201909064RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT 011101 V III °nolo olommonmoiloiflo VII IE (10) International Publication Number WO 2018/178040 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61K 31/5386 (2006.01) C07K 16/28 (2006.01) A61P 35/00 (2006.01) A61K 31/519 (2006.01) A61N 5/00 (2006.01) A61K 31/5377 (2006.01) (21) International Application Number: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 17163837.2 17204926.4 PCT/EP2018/057708 27 March 2018 (27.03.2018) English English 30 March 2017 (30.03.2017) EP 01 December 2017 (01.12.2017) EP (71) Applicants: MERCK PATENT GMBH [DE/DE]; Frank- furter Strasse 250, 64293 Darmstadt (DE). PFIZER INC. [US/US]; 235 East 42nd Street, NEW YORK, NY 10017 (US). (72) Inventors: ZIMMERMANN, Astrid; Pfaffengasse 12, 64367 MUEHLTAL (DE). DAMSTRUP, Lars; Jesper- vej 100, 3400 HILLEROED (DK). PROKEIN, Anne- Kathrin; Bluetenweg lc, 64380 ROSSDORF (DE). (74) Agent: VALLAZZA, Marco; Merck Serono Sa Intellectu- al Property, c/o Merck Patent GmbH, 64271 DARMSTADT (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: COMBINATION OF AN ANTI-PD-Ll ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CAN- CER (57) : The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises an anti-PD-L antibody and a DNA-PK inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-Ll expression. 1-1 O 71- O 00 N 1-1 00 1-1 O C
SG11201909064R 2017-03-30 2018-03-27 Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer SG11201909064RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17163837 2017-03-30
EP17204926 2017-12-01
PCT/EP2018/057708 WO2018178040A1 (en) 2017-03-30 2018-03-27 Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201909064RA true SG11201909064RA (en) 2019-10-30

Family

ID=61899231

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909064R SG11201909064RA (en) 2017-03-30 2018-03-27 Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG10202110707UA SG10202110707UA (en) 2017-03-30 2018-03-27 Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202110707UA SG10202110707UA (en) 2017-03-30 2018-03-27 Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Country Status (13)

Country Link
US (2) US20200048352A1 (en)
EP (1) EP3600410A1 (en)
JP (1) JP7166278B2 (en)
KR (1) KR102644408B1 (en)
CN (1) CN110494161A (en)
AU (1) AU2018241774A1 (en)
BR (1) BR112019019939A2 (en)
CA (1) CA3058276A1 (en)
IL (1) IL269718A (en)
MX (1) MX2019011657A (en)
RU (1) RU2765997C2 (en)
SG (2) SG11201909064RA (en)
WO (1) WO2018178040A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170132171A (en) * 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 Pd-1 / pd-l1 inhibitors for the treatment of cancer
KR20180018762A (en) 2015-06-16 2018-02-21 메르크 파텐트 게엠베하 Pd-l1 antagonist combination treatments
US11274154B2 (en) 2016-10-06 2022-03-15 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
BR112019025188A2 (en) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME
CN113365659B (en) * 2019-01-31 2023-08-18 正大天晴药业集团股份有限公司 Use of anti-PD-L1 antibodies for the treatment of head and neck cancer
WO2020259613A1 (en) * 2019-06-27 2020-12-30 南京明德新药研发有限公司 Quinazoline and cinnoline derivatives as dna-pk inhibitor
CA3227836A1 (en) * 2021-08-17 2023-02-23 Michael Paul Wheatcroft Combination radiotherapy
WO2023232100A1 (en) * 2022-06-02 2023-12-07 正大天晴药业集团股份有限公司 Pharmaceutical combination for treating uterine malignant tumor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12467A (en) 1855-02-27 And jas
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
BR9813365A (en) 1997-12-05 2004-06-15 Scripps Research Inst Method for Production and Humanization of a Mouse Monoclonal Antibody
JP5252635B2 (en) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド Human monoclonal antibody against programmed death ligand 1 (PD-L1)
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
LT4209510T (en) 2008-12-09 2024-03-12 F. Hoffmann-La Roche Ag Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
PT2504364T (en) 2009-11-24 2017-11-14 Medimmune Ltd Targeted binding agents against b7-h1
EP2612151B1 (en) 2010-08-31 2017-08-09 Genentech, Inc. Biomarkers and methods of treatment
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
DE102013008118A1 (en) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CA2926856A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
SG11201606577YA (en) * 2014-02-10 2016-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
JP2017530950A (en) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド Combination of PD-1 antagonist and ALK inhibitor for treating cancer
US20180125988A1 (en) * 2014-11-11 2018-05-10 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
KR20170132171A (en) * 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 Pd-1 / pd-l1 inhibitors for the treatment of cancer
US20180044429A1 (en) * 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
KR20180018762A (en) * 2015-06-16 2018-02-21 메르크 파텐트 게엠베하 Pd-l1 antagonist combination treatments

Also Published As

Publication number Publication date
US20230272083A1 (en) 2023-08-31
SG10202110707UA (en) 2021-11-29
MX2019011657A (en) 2019-11-18
RU2019133787A (en) 2021-04-30
JP7166278B2 (en) 2022-11-07
AU2018241774A1 (en) 2019-11-14
IL269718A (en) 2019-11-28
KR102644408B1 (en) 2024-03-07
BR112019019939A2 (en) 2020-04-28
RU2765997C2 (en) 2022-02-07
US20200048352A1 (en) 2020-02-13
WO2018178040A1 (en) 2018-10-04
CN110494161A (en) 2019-11-22
JP2020515609A (en) 2020-05-28
RU2019133787A3 (en) 2021-08-10
CA3058276A1 (en) 2018-10-04
EP3600410A1 (en) 2020-02-05
KR20190135028A (en) 2019-12-05

Similar Documents

Publication Publication Date Title
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201908391XA (en) Methods for modulating an immune response
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201811432WA (en) Rna for cancer therapy
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900442PA (en) Sorting of t lymphocytes in a microfluidic device
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201901389XA (en) Combination therapy with glutaminase inhibitors